Navigation Links
UofL physicians, Jewish Hospital first in Kentucky to offer new aortic valve replacement

Louisville, Ky. Some individuals with severe aortic stenosis also known as narrowing of the aortic valve in the heart who are not well enough to undergo open heart surgery have a new treatment option thanks to a new procedure now available in Kentucky from University of Louisville physicians at Jewish Hospital.

A team that included UofL cardiologists Michael Flaherty, M.D, Ph.D., and Naresh Solankhi, M.D., and UofL cardiothoracic surgeon Matthew Williams, M.D., performed the first transcatheter aortic-valve replacement (TAVR) procedure on a 47-year-old male patient on Dec. 21, 2011.

During the procedure a biological valve was inserted through a catheter and implanted within a diseased aortic valve. The procedure allows for valve replacement without traditional open-heart surgery and while the heart is beating, therefore avoiding cardiopulmonary bypass.

It is the only valve replacement option for patients with severe aortic stenosis who are not well enough to undergo traditional open-heart surgery, Flaherty said. Most patients will avoid any surgery in their chest.

"For patients who qualify, the TAVR procedure is often their last hope for treatment of their heart disease," said Flaherty, who is assistant professor of medicine, physiology and biophysics and director of research-interventional cardiology in UofL's Department of Medicine. "It's a unique procedure, and we are once again proud to be on the cutting edge of heart care in the region."

During the TAVR procedure, a cardiologist and cardiothoracic surgeon work together to implant the new heart valve, called the Edwards SAPIEN valve, which is made from cow tissue and developed by Edwards Lifesciences Corp.

The valve is inserted into the body through a small cut in the leg. Once delivered to the site of the patient's diseased valve, the Edwards SAPIEN valve is expanded with a balloon and immediately functions in place of the patient's valve.

Jewish Hospital is one of 29 sites in the United States where researchers are now studying the Edwards SAPIEN transcatheter aortic heart valve and the next-generation Edwards SAPIEN XT valve as part of an ongoing national clinical trial called the PARTNER II Trial. The Edwards SAPIEN valve studied in the first PARTNER Trial and used in Europe since 2007 recently received FDA approval for the treatment of inoperable patients in the United States. This is the first U.S. commercial approval for a transcatheter device enabling aortic valve replacement without the need for open-heart surgery.

"The availability of the TAVR procedure marks a major milestone in the treatment of valve-related heart disease," said Williams, who practices with University Cardiothoracic Surgical Associates and is assistant professor of thoracic and cardiovascular surgery in the Department of Surgery at UofL. "It gives us another tool to help take care of people. Older folks, who would prefer to avoid surgery if they can, will be the patients who will most often benefit."


Contact: Jill Scoggins
University of Louisville

Related biology news :

1. Analysis of Ashkenazi Jewish genomes reveals diversity, history
2. NIH awards National Jewish Health $31 million to lead study of infections associated with eczema
3. Gregory Downey, M.D., of National Jewish Health, honored for scientific accomplishments
4. National Jewish Health researchers discover how virulent bacteria
5. New genetic research indicates Jewish priesthood has multiple lineages
6. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
7. Researchers at National Jewish Health evaluating a treatment
8. New disinfection technique could revolutionize hospital room cleaning
9. Brigham and Womens Hospital awarded $9.6 million to study whole genome sequencing
10. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
11. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
Post Your Comments:
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
Breaking Biology Technology: